Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript
05:44pm, Tuesday, 05'th Aug 2025
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
09:16am, Tuesday, 05'th Aug 2025
Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
07:00am, Tuesday, 05'th Aug 2025
CONSHOHOCKEN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term
05:49pm, Thursday, 31'st Jul 2025
Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients. Key catalysts include
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
08:00am, Friday, 25'th Jul 2025
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
12:35pm, Thursday, 17'th Jul 2025
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
08:11am, Thursday, 17'th Jul 2025
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 16'th Jul 2025
CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
• Provides Protection Through Sept. 2044; Will Be Listed in FDA's Orange Book CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
07:35am, Friday, 20'th Jun 2025
Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease nonci
CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 17'th Jun 2025
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
08:00am, Monday, 02'nd Jun 2025
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care
